Broadfin Capital LLC Has Cut Its Mirati Therapeutics INC (MRTX) Holding by $20.76 Million as Market Valuation Rose

Mirati Therapeutics, Inc. (NASDAQ:MRTX) LogoInvestors sentiment increased to 2.38 in 2018 Q2. Its up 0.62, from 1.76 in 2018Q1. It is positive, as 20 investors sold MRTX shares while 12 reduced holdings. 50 funds opened positions while 26 raised stakes. 25.75 million shares or 31.83% more from 19.53 million shares in 2018Q1 were reported. Bnp Paribas Arbitrage reported 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Driehaus Cap Lc invested in 441,470 shares. Walleye Trading Limited Liability holds 0% or 6,155 shares in its portfolio. Alliancebernstein Ltd Partnership reported 29,400 shares. Citadel Ltd Com invested in 0% or 13,489 shares. Swiss Natl Bank has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Federated Inc Pa has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Farallon Cap Management Lc has invested 0.23% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). 24,631 were accumulated by Citigroup. 253,941 are owned by Invesco Ltd. The Massachusetts-based Wellington Management Group Inc Ltd Liability Partnership has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Wells Fargo Mn reported 10,453 shares. Hightower Advsr Limited Liability Corporation holds 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 4,250 shares. Retail Bank Of Montreal Can invested in 129 shares or 0% of the stock. Bankshares Of Mellon holds 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 110,138 shares.

Since June 7, 2018, it had 0 buys, and 2 selling transactions for $3.48 million activity. The insider Christensen Jamie sold 10,207 shares worth $501,630. BAUM CHARLES M sold $2.98 million worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Thursday, August 23. $15.54 million worth of stock was bought by venBio Select Advisor LLC on Monday, June 11.

Broadfin Capital Llc decreased its stake in Mirati Therapeutics Inc (MRTX) by 29.35% based on its latest 2018Q2 regulatory filing with the SEC. Broadfin Capital Llc sold 423,770 shares as the company’s stock rose 14.32% with the market. The hedge fund held 1.02M shares of the health care company at the end of 2018Q2, valued at $50.30 million, down from 1.44M at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Mirati Therapeutics Inc for a number of months, seems to be less bullish one the $1.27B market cap company. The stock decreased 1.61% or $0.64 during the last trading session, reaching $39.12. About 432,468 shares traded. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has risen 1024.49% since December 8, 2017 and is uptrending. It has outperformed by 1008.87% the S&P500.

Broadfin Capital Llc, which manages about $1.26B and $635.22M US Long portfolio, upped its stake in Adma Biologics Inc (NASDAQ:ADMA) by 2.53M shares to 3.25 million shares, valued at $14.66M in 2018Q2, according to the filing. It also increased its holding in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 281,918 shares in the quarter, for a total of 1.42M shares, and has risen its stake in Strata Skin Sciences Inc.

Analysts await Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report earnings on March, 14. They expect $-0.80 earnings per share, down 19.40 % or $0.13 from last year’s $-0.67 per share. After $-0.85 actual earnings per share reported by Mirati Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -5.88 % EPS growth.

More notable recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Seekingalpha.com which released: “Mirati Therapeutics: How Much Higher Can This ‘Rocket’ Go? – Seeking Alpha” on June 21, 2018, also Streetinsider.com with their article: “Mirati Therapeutics (MRTX) Announces FDA Clearance of IND to Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849 – StreetInsider.com” published on November 29, 2018, Nasdaq.com published: “Week Ahead In Pharmaceuticals: 11 Stocks To Watch (MRTX, EPZM, ITCI…) – Nasdaq” on October 22, 2018. More interesting news about Mirati Therapeutics, Inc. (NASDAQ:MRTX) were released by: Benzinga.com and their article: “Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results, IPOs (Nov. 11-17) – Benzinga” published on November 11, 2018 as well as Nasdaq.com‘s news article titled: “Notable Tuesday Option Activity: VMW, NVDA, MRTX – Nasdaq” with publication date: October 09, 2018.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.